Dublin, Jan. 13, 2017 -- Research and Markets has announced the addition of the "Biosimilars Market by Product, Manufacturing, Application - Global Forecast to 2021" report to their offering.
The biosimilars market is expected to reach USD 10.90 Billion by 2021 from USD 3.39 Billion in 2016, at a CAGR of 26.3%.
The global biosimilars market is segmented on the basis of product, manufacturing type, and application. Factors such as rising incidence of various diseases, increasing demand for biosimilar drugs due to their cost-effectiveness, growing pressure to curtail healthcare expenditure, rising geriatric population, strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars, and increasing government support and initiatives to develop and promote biosimilars are expected to drive the growth of this market.
Emerging markets and new indications and patent expiry of biologic products has opened an array of opportunities for players in the biosimilars market. However, complexities in manufacturing and innovative strategies by biologic drug manufacturers are expected to restrain the growth of this market to a certain extent during the forecast period.
The key players in the biosimilars market include:
- Amgen Inc.
- Biocon Ltd.
- Celltrion Inc.
- Dr. Reddy's Laboratories
- F. Hoffmann-La Roche Ltd.
- Mylan Inc.
- Pfizer Inc.
- Samsung Bioepis
- Sandoz International Gmbh (A Division of Novartis International Ag)
- Teva Pharmaceutical Industries Ltd.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Biosimilars Market, by Type of Product
7 Biosimilars Market, by Type of Manufacturing
8 Biosimilars Market, by Application
9 Biosimilars Market, by Region
10 Competitive Landscape
11 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/kb6hn6/biosimilars
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biosimilars and Biosuperiors


Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Apple Turns 50: From Garage Startup to AI Crossroads
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 



